Oh dear, oh dear an EGM to give our fast-talking but slow-acting execs more incentive. Really...and what happened to the last swathe of incentive - did it die "on the vine" as it were through oversight...did I miss a return to 8op?
No? you mean it's still about 25p like it was ages ago with the risk of an exec take-over?
SO "what" has happened since them? Where is the incentive for shareholders?
Ah! there's the real issue - don't pay the execs until they produce some sales and profits.
Grief, we can't insist they perform properly - where would it end?

When I was employed, one took pride in doing a job well...and that usually meant better than the lowest acceptable - otherwise your card was marked!

Oh well, maybe this is an EGM worth paying for? - can't execs work without such interruptions....securing a deal or some trial success would be nice -
Skypharma - says it all - pie-pharma more likely - perhaps we should insist on a name-change to reflect the executives likely successes.

Let's guess that there is a deal in the offing and they expect this will move the sp from 25p to 50p - SO What! - where is the 80p?
Now let's say that 80p was the sp for neutral returns ( for may investors)...therefore if the execs can achieve 160p (steady for, say 3 months) then they will have achieved something and "might" be worth a bonus of 10% salary......increased to 20% if the company is generating profits such that the bank-balance is real (ie above any outstanding loans/debts/liabilities) nad there is no cash-call during the next 12 months (with the sp remaining at 1.60-level)...only then would the bonus be paid. Any exec that can't hack it, or is shoved out etc. forfeits their bonuses and must repay any already paid.

Makes me mad these Options, incentive plans etc - have they no shame?
Get on with your work!

[ the bonus is to be paid 100% of salary if the sp reaches 55p - but there is a "initial grant" of up to 300% of salary for the top execs- ouch! - see documents - and DYOR ]

Looks pretty easy to me! A year ago it was 40p - shouldn't investments go up?
They could show some belief in the company by buying shares...say 100k's at 40p - would make the market think. (That's each.... ).

Grr - does any other shareholder feel cheated from the Action?

Good recovery in sp today after the initial drop following the rns.

COMMENT, here

A new low starting to look interesting.

HI driver/// BOTTOM FISHING (AGAIN)????????????

bristlelad
I like a bit of BOTTOM

little bit of bottom feeding going on at skp

Hi folks............

Don't like the chart at all, on this one .................. looking to fall very soon.

All views welcome.

Cheers
Amar

Today's good news is a small payment in Dollars, as a result of an FDA approval - but it's not done much - it isn't much as Cash.

BUT - and here maybe we might see some activity if Punters move this stock - we do know SKP isn't dead in the water - The...(Titanic Mode)...Ship has sunk without trace but the lifeboat has come back - at least I think that;s what it is (in the Dark)......brr!
Currently 13p this is SKP's all-time low ( it was 10p before others acted).....is there anything else to get excited about, OR will it die down once past the jetsom surrounding the last known co-ordinates?
It might come good - but only in TIME - and That's "key", IMHO, to the sp - it may still dip further with.... " Market Woes generally".

This is hitting all time lows could see 5p before the bounce.

Yes, Driver, and today it has touched that level....Oh deary and we investors were led to believe things were quite rosy - all those years ago.

Were we lied to? -OR- was the executive a total shambles, which we should have realised?

I recall this was close to 1 with talk of nano-technology curing all ills.

Maybe there was a hint in the name - "sky - "

Arrgh!

Nearly bought in today I was still pondering after the bell so to late still on the watch list.

Bought in today.

Good timing for a change up 14%

SkyePharma low to mid single digit royalties on GSK's US Requip XL approval
AFX


LONDON (Thomson Financial) - British drug delivery specialist SkyePharma Plc has announced that it is in line for low-to mid-single digit royalties after development partner GlaxoSmithKline Plc announced on Friday that US authorities have given approval for its Requip XL Parkinson's Disease drug.

The drug uses SkyePharma's patented Geomatrix technology which allows for continuous delivery of ropinirole, the active ingredient of Requip KL, over 24 hours to provide smooth blood levels.

The drug is expected to hit the US market in mid July.

The Requip XL approval is a major milestone for SkyePharma, providing it with a much-needed further revenue stream.

The company is waiting for all of the phase III results for its asthma treatment Flutiform before it starts talks with holders of put options for 69 million pounds convertible bonds which are due at the earliest in May 2009, and further put options for 20 million pounds due in June 2010 at the earliest.

Requip XL is currently approved in 23 countries in Europe for the treatment of Parkinson's disease.

ben.deighton@thomsonreuters.com

SkyePharma says second set of Flutiform phase III trial results successful
AFX


LONDON (Thomson Financial) - SkyePharma Plc., said its second Phase III efficacy study for its Flutiform asthma treatment has successfully met its endpoints and furthers the product's progress towards its regulatory filing with the U.S. Food and Drug Administration.

This is the second of several clinical efficacy studies being carried out in preparation for regulatory filing in the first quarter of 2009.

The results of the final Phase III study for Flutiform are due later this year.

The news should give the beleaguered biotech a much-needed boost ahead of negotiations with its bondholders over the company's 89 million pounds of convertible debt, the bulk of which is due for repayment in May next year.

julian.hofmann@thomsonreuters.com

I wonder why it's not 50p by now!!!
MMs' usual game...

FDA appreoval is no G'tee of shareholder returns- Directors always have someting elst to waste our money on.
The convertible loan is a huge drag and until SKP gets a commercial partner, there are no sales.
Being "distressed" any partner may want a larger slice of profits, to allow their name to be associated with this dullard.
- All-in-all, IMHO it's not surprising we are so far from 50p.

Currently 6p, the Mkt Cap is 45m - goodness what is supporting this valuation?....I hold but fear it may be too late. Earlier expectations have been dashed.

Driver, what are your estimates, having bought recently...etc.

Great news. This company worth a couple of times more than the current price. We need a large company to bid for it.

Companies which their share is not held by banks can rise. Those which are held by banks have to go down.
WHat do you think?

Some big buys today 1.8m and 2m